Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 04:31 ET | Source: Research and Markets

Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Outlook

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Peptide Drug Conjugate Market Opportunity, Drug Sales, Patent, Price, Dosage, Proprietary Technologies & Clinical Trials Outlook 2031" report has...
April 21, 2026 04:27 ET | Source: Research and Markets

Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Targeted Alpha Therapy Market Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications & Clinical Trials Insight 2030"...
April 20, 2026 12:24 ET | Source: Research and Markets

Site Management Organization Market Report 2026-2035 with Insights by Therapeutic Area, Trial Phases, Clinical Trial Components, Type of Interventions and Region

Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Site Management Organization Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Trial Phases, Clinical Trial...
April 15, 2026 09:10 ET | Source: Research and Markets

Pharmacovigilance Aspects of Licensing Agreements Course: Review of Existing Global Requirements (ONLINE EVENT: June 25, 2026)

Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Pharmacovigilance Aspects of Licensing Agreements (June 25, 2026)" training has been added to ResearchAndMarkets.com's offering.This intensive...
April 15, 2026 08:00 ET | Source: Callio Therapeutics

Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026

At AACR 2026, Callio Therapeutics will present data that highlight the potential of CLIO-8221 as a therapeutic option for HER2-expressing cancers
April 15, 2026 07:00 ET | Source: Beeline Medicines Corporation

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead program afimetoran, a potential...
April 14, 2026 04:15 ET | Source: Research and Markets

AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026)

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "AI in Pharmacovigilance (May 18, 2026)" training has been added to ResearchAndMarkets.com's offering.This course will provide a comprehensive...
April 14, 2026 04:05 ET | Source: Research and Markets

1 Day Pharmacovigilance Training Course: An Overview of Drug Safety from Safety Collection to Regulatory Inspection (ONLINE EVENT: Apr 30, 2026)

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Pharmacovigilance: An Overview of Drug Safety from Safety Collection to Regulatory Inspection (Apr 30, 2026)" training has been added to ...
April 13, 2026 05:08 ET | Source: Research and Markets

NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "NRG Fusion - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report delivers in-depth analysis on the...
April 08, 2026 09:15 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...